ResearcherThe University of Texas Rio Grande ValleyActive in the last 2 years

Debasish Bandyopadhyay

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-2726-5127; OpenAlex author ID A5050203638. Sources: OpenAlex.

Their work

Papers: 2 (first author 0, last author 2)
Trials: 0
Grants: 0
Labs led: 1
Collaborators: 3

Papers, trials and grants by year

2023: 1 paper · 2024: none · 2025: none · 2026: 1 paper

Papers 2

Targeted Therapy in Hepatobiliary Pancreatic Cancer (HPC): Advantages and Advancements of Antibody Drug Conjugates, a Type of Chemo-Biologic Hybrid Drugs. Last author DOI 10.3390/ijms27062707 ↗
Molecular Research in Pancreatic Cancer: Small Molecule Inhibitors, Their Mechanistic Pathways and Beyond. Last author DOI 10.3390/cimb45030124 ↗

Closest collaborators

The 3 strongest of 3 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

Tushar Deb Nath · 1 shared paper, 2026 · strength 0.43
- Paper Targeted Therapy in Hepatobiliary Pancreatic Cancer (HPC): Advantages and Advancements of Antibody Drug Conjugates, a T… DOI 10.3390/ijms27062707 ↗
Subhash C. Chauhan · 1 shared paper, 2026 · strength 0.43
- Paper Targeted Therapy in Hepatobiliary Pancreatic Cancer (HPC): Advantages and Advancements of Antibody Drug Conjugates, a T… DOI 10.3390/ijms27062707 ↗
Shaila A. Shetu · 1 shared paper, 2023 · strength 0.26
- Paper Molecular Research in Pancreatic Cancer: Small Molecule Inhibitors, Their Mechanistic Pathways and Beyond. DOI 10.3390/cimb45030124 ↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.